<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526734</url>
  </required_header>
  <id_info>
    <org_study_id>ERA-2006-001</org_study_id>
    <secondary_id>CDR0000561733</secondary_id>
    <secondary_id>ERA-NEUMOBIL</secondary_id>
    <secondary_id>EUDRACT-2006-000891-34</secondary_id>
    <nct_id>NCT00526734</nct_id>
  </id_info>
  <brief_title>High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma</brief_title>
  <official_title>A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, use different ways to stop cancer&#xD;
      cells from dividing so they stop growing or die. Stem cell transplant using stem cells from&#xD;
      the patient may be able to replace immune cells that were destroyed by chemotherapy used to&#xD;
      kill cancer cells. Giving colony-stimulating factors, such as G-CSF or pegfilgrastim, helps&#xD;
      stem cells move from the bone marrow to the blood so they can be collected. It is not yet&#xD;
      known which regimen is more effective in treating multiple myeloma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well high-dose chemotherapy followed&#xD;
      by stem cell transplant works in treating patients with newly diagnosed stage I, stage II, or&#xD;
      stage III multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare engraftment of peripheral blood progenitor cells (PBPCs) mobilized by 2&#xD;
           different fixed doses of pegfilgrastim versus a by-weight dose of filgrastim (G-CSF).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the ability of 2 different fixed doses of pegfilgrastim to mobilize PBPCs.&#xD;
&#xD;
        -  Determine the safety of pegfilgrastim during PBPC mobilization and collection.&#xD;
&#xD;
        -  Determine the effect of different induction chemotherapy regimens on autologous&#xD;
           progenitor cell transplantation.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified by type of induction&#xD;
      chemotherapy (Thal/Dex vs VAD vs Vel-Dex vs VTD) and by stage of disease according to&#xD;
      International Prognostic Index criteria (stage I [i.e., beta-2 microglobulin &lt; 3.5 and&#xD;
      albumin &gt; 35] vs stages II and III).&#xD;
&#xD;
        -  Induction therapy: Patients receive 3-4 courses of 1 of the following regimens:&#xD;
&#xD;
             -  VAD: Patients receive vincristine, doxorubicin hydrochloride, and dexamethasone.&#xD;
&#xD;
             -  Thal/Dex: Patients receive thalidomide and dexamethasone.&#xD;
&#xD;
             -  Vel-Dex: Patients receive bortezomib and dexamethasone.&#xD;
&#xD;
             -  VTD: Patients receive bortezomib, thalidomide, and dexamethasone. Patients&#xD;
                achieving complete, partial, or minimal response after 3-4 courses of induction&#xD;
                therapy proceed to peripheral blood progenitor cell (PBPC) mobilization 17 days&#xD;
                after completion of induction therapy.&#xD;
&#xD;
        -  PBPC mobilization: Patients are randomized to 1 of 3 arms.&#xD;
&#xD;
             -  Arm I: Patients receive filgrastim subcutaneously (SC) once daily until the final&#xD;
                leukapheresis.&#xD;
&#xD;
             -  Arm II: Patients receive a single dose of pegfilgrastim SC.&#xD;
&#xD;
             -  Arm III: Patients receive pegfilgrastim as in arm II at a higher dose.&#xD;
&#xD;
        -  Leukapheresis: Patients undergo up to 3 leukaphereses to obtain adequate numbers of&#xD;
           CD34-positive filgrastim- or pegfilgrastim-mobilized PBPCs for engraftment. Patients&#xD;
           achieving a sufficient number of collected PBSCs proceed to conditioning chemotherapy.&#xD;
&#xD;
        -  Conditioning chemotherapy: Patients receive high-dose melphalan* IV over 1-2 days.&#xD;
           Patients then proceed to PBPC transplantation.&#xD;
&#xD;
      NOTE: *Patients ≥ 65 years old receive melphalan at a lower dose.&#xD;
&#xD;
        -  Autologous PBPC transplantation: Patients undergo infusion of PBPCs on day 0. Patients&#xD;
           in all arms receive G-CSF support beginning on day 1 after PBPC transplantation and&#xD;
           continuing until blood counts recover for 3 consecutive days.&#xD;
&#xD;
      After completion of study therapy, patients are followed for up to 100 days&#xD;
      post-transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with engraftment after induction chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of patients from whom ≥ 2 x 10e6 CD34-positive cells/kg are harvested</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of patients from whom ≥ 4 x 10e6 CD34-positive cells/kg are harvested</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34-positive cells/kg yield in each leukapheresis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of leukaphereses to collect ≥ 2 x 10e6 CD34-positive cells/kg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of leukaphereses to collect ≥ 4 x 10e6 CD34-positive cells/kg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with platelet recovery ≥ 20 x 10e9/L in the absence of transfusion for at least 7 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ANC recovery of ≥ 0.5 x 10e9/L</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil recovery, defined as the time to neutrophil engraftment (i.e., ANC ≥ 0.5 x 10e9/L for 3 consecutive days)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC ≥ 1.0 x 10e9/L</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet recovery, defined as the time to platelets ≥ 20 x 10e9/L in the absence of platelet transfusion support for at least 7 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of hospitalization during mobilization phase and during post-transplantation phase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events during and after the use of pegfilgrastim 12 mg or pegfilgrastim 18 mg and filgrastim</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of symptomatic stage I or stage II-III multiple myeloma&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
          -  No amyloidosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1.0 x 10^9/L (without colony-stimulating factors)&#xD;
&#xD;
          -  Platelet count ≥ 50 x 10^9/L (without transfusion support within the past 7 days)&#xD;
&#xD;
          -  Serum calcium &lt; 14 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Willing and able to comply with protocol requirements&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  Uncontrolled angina&#xD;
&#xD;
          -  Severe uncontrolled ventricular arrhythmia&#xD;
&#xD;
          -  Acute ischemia or active conduction system abnormalities as evidenced by ECG&#xD;
&#xD;
          -  Serious medical condition that could prolong hematological recovery or preclude&#xD;
             completion of or tolerance to protocol therapy&#xD;
&#xD;
          -  Seropositive for HIV antibody&#xD;
&#xD;
          -  Known hepatitis B surface antigen positivity OR active hepatitis C infection&#xD;
&#xD;
          -  Active systemic infection requiring treatment&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Poor psychiatric condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No plasmapheresis within the past 4 weeks&#xD;
&#xD;
          -  No major surgery within the past 4 weeks&#xD;
&#xD;
          -  No anticancer therapy within the past 5 years, except treatment for basal cell&#xD;
             carcinoma of the skin or carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  No other concurrent G-CSF growth factors&#xD;
&#xD;
          -  No concurrent enrollment in another investigational clinical trial&#xD;
&#xD;
          -  No concurrent investigational agent that would contraindicate the use of pegfilgrastim&#xD;
             as either a mobilization agent or a hematological recovery agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Feremans, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Feremans, MD, PhD</last_name>
      <phone>32-2-555-3660</phone>
      <email>wfereman@ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej W. Hellmann, MD, PhD</last_name>
      <phone>48- 58-349-2230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silesian Medical Academy</name>
      <address>
        <city>Katowice</city>
        <zip>40-029</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerzy Holowiecki, MD, PhD</last_name>
      <phone>48-32-256-2858</phone>
      <email>holow@slam.katowice.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology and Blood Transfusion</name>
      <address>
        <city>Warsaw</city>
        <zip>00-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Warzocha, MD, PhD</last_name>
      <phone>48-22-849-8507</phone>
      <email>warzocha@ihit.waw.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

